Benzinga | Jan 20, 2021 08:03AM EST

Ocular Therapeutix Highlights Presentation Of Interim Topline Data From Phase 1 Clinical Trial Of OTX-TIC In Patients With Primary Open Angle Glaucoma Or Ocular Hypertension At 10th Annual Glaucoma 360 New Horizons Forum

Ocular Therapeutix(tm), Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced plans to present data on OTX-TIC, a travoprost intracameral implant for the treatment of patients with primary open angle glaucoma or ocular hypertension at the Glaucoma 360 New Horizons Forum being held virtually on January 30th. As part of the event, Michael Goldstein, M.D., M.B.A., President, Ophthalmology and Chief Medical Officer of Ocular Therapeutix, has narrated a presentation on the OTX-TIC Phase 1 study that is available today and can be accessed on the "Events and Presentations" section of the Ocular Therapeutix website.